立方体治疗与心脏衰竭的风险较低的患者与心房动相关:一个基于人口的研究
Jia-Yi Huang1,2, Yap-Hang Chan2, Yi-Kei Tse2
1Division of Cardiology, Department of Medicine The University of Hong Kong Shen Zhen Hospital Hong Kong China.
Journal of the American Heart Association
|November 28, 2023
概括
静止剂的使用显著降低了心房动患者心力衰竭的风险. 这种益处随着他类药物持续时间的延长而增加,这表明随着时间的推移,它具有保护作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 关于他类药物在降低心力衰竭 (HF) 风险中的作用存在争议.
- 这项研究调查了在心房动 (AF) 患者中,他类药物治疗和HF发病率之间的关联.
研究的目的:
- 评估他类药物使用对被诊断患有心房动的个人中发生性心力衰竭的风险的影响.
主要方法:
- 使用了一组新诊断的心房动患者 (2010-2018).
- 在他类药物使用者 (n=23,239) 和非使用者 (n=29,251) 之间的共变量平衡中使用治疗权重的逆概率.
- 使用考克斯比例危险模型和竞争性风险回归评估事件HF风险.
主要成果:
- 在平均5.1年的随访期间,病例性HF发生在15.8%的他类药物使用者中,而非使用者中为19.1%.
- 立方体使用与19%降低HF风险有关 (aSHR,0.81;95% CI,0.78-0.85).
- 长时间使用他类药物时,观察到与持续时间相关的HF风险降低.
结论:
- 在心房动患者中,他类药物治疗与发生性心力衰竭的风险降低有关.
- 类药物对HF风险的保护作用似乎取决于持续时间,使用时间较长会带来更大的益处.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
671
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
671
Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
845
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
845
Heart Failure Drugs: Diuretics
396
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396


